Catalyst Pharmaceutical Partners COO Purchases $217,000 in Stock (CPRX)

Share on StockTwits

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) COO Steve Miller purchased 100,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 4th. The shares were purchased at an average cost of $2.17 per share, for a total transaction of $217,000.00. Following the transaction, the chief operating officer now directly owns 214,754 shares in the company, valued at approximately $466,016. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded up 1.41% during mid-day trading on Wednesday, hitting $2.16. 487,507 shares of the company’s stock traded hands. Catalyst Pharmaceutical Partners has a 52 week low of $0.83 and a 52 week high of $3.65. The stock has a 50-day moving average of $1.97 and a 200-day moving average of $2.0. The company’s market cap is $145.1 million.

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last announced its earnings results on Friday, May 16th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.01. On average, analysts predict that Catalyst Pharmaceutical Partners will post $-0.27 earnings per share for the current fiscal year.

CPRX has been the subject of a number of recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Catalyst Pharmaceutical Partners in a research note on Monday, April 14th. They set an “overweight” rating and a $4.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Catalyst Pharmaceutical Partners in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Catalyst Pharmaceutical Partners presently has a consensus rating of “Buy” and an average target price of $3.41.

Catalyst Pharmaceutical Partners, Inc is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Biogen Idec Sales and Profit Fly Past Projections
Biogen Idec Sales and Profit Fly Past Projections
OneWest Bank to be Acquired by CIT in $3.4 Billion Deal
OneWest Bank to be Acquired by CIT in $3.4 Billion Deal
Security Cost for TSA Increases on Monday
Security Cost for TSA Increases on Monday
Asian Investor Acquire Forbes
Asian Investor Acquire Forbes
Crossovers and SUVs Most Popular Vehicles in U.S.
Crossovers and SUVs Most Popular Vehicles in U.S.
AbbVie Finally Reaches Deal for Shire
AbbVie Finally Reaches Deal for Shire


Leave a Reply

 
© 2006-2014 WKRB News.